研究者
J-GLOBAL ID:202001017418706062
更新日: 2024年08月21日
齋藤 良太
SAITO RYOTA
競争的資金等の研究課題 (1件):
- 2022 - 2025 Keap1-Nrf2システムに着目した慢性閉塞性肺疾患の発症メカニズムの解明
論文 (25件):
-
Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, et al. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC. Cancer biomarkers : section A of Disease markers. 2024
-
Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, Makoto Maemondo. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers. 2023. 15. 17
-
Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, et al. A retrospective study of the efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR-TKI monotherapy for PD-L1-positive EGFR-mutant non-small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncology letters. 2023. 26. 2. 334-334
-
木村 望, 突田 容子, 渋谷 里紗, 宮内 栄作, 角藤 翔, 成田 大輔, 斎藤 良太, 杉浦 久敏. 肺癌 効果予測因子 非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索. 日本呼吸器学会誌. 2023. 12. 増刊. 194-194
-
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, et al. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thoracic cancer. 2022. 14. 2. 168-176
もっと見る
MISC (10件):
-
突田 容子, 宮内 栄作, 斎藤 良太, 佐藤 輝幸, 山本 貴也, 片桐 佑, 井上 彰, 一ノ瀬 正和. 強度変調放射線治療による根治的化学放射線療法後のデュルバルマブ使用経験の報告. 肺癌. 2019. 59. 6. 674-674
-
Atsushi Nakamura, Akira Inoue, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada, Shingo Takanashi, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita, et al. Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY. 2014. 32. 15
-
Ryota Saito, Akira Inoue, Shunichi Sugawara, Satoshi Oizumi, Makoto Maemondo, Koichi Okudera, Toshiro Suzuki, Kazuhiro Usui, Masao Harada, Naoto Morikawa, et al. Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802. JOURNAL OF CLINICAL ONCOLOGY. 2012. 30. 15
-
Keita Kudo, Makoto Nishio, Kazuko Sakai, Azusa Tanimoto, Toshio Sakatani, Ryota Saito, Kyohei Kaburaki, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, et al. Detection of EML4-ALK in serum RNA from lung cancer patients using MassARRAY platform. JOURNAL OF CLINICAL ONCOLOGY. 2012. 30. 15
-
Noriko Yanagitani, Toshio Sakatani, Ryota Saito, Hisashi Tanaka, Kyohei Kaburaki, Keita Kudo, Atsushi Horiike, Fumiyoshi Ohyanagi, Sachiko Hagiwara, Takeshi Horai, et al. IMPACT OF THE 7TH EDITION OF TNM CLASSIFICATION (UICC7) IN NON-SURGICAL CASES OF ADVANCED NON-SMALL CELL LUNG CANCER. JOURNAL OF THORACIC ONCOLOGY. 2011. 6. 6. S1167-S1168
もっと見る
前のページに戻る